The IP & Science Business of Thomson Reuters has announced a strategic initiative with NuMedii. The companies will leverage high-quality data, knowledge and predictive technologies to identify therapeutic candidates with the greatest probability for clinical success.
Our collaboration with NuMedii is an opportunity to combine the leading information sources available with novel analytics, data integration and biomedical expertise in a way that has not been done before outside of a laboratory environment,” said Joe Donahue, senior vice president, Thomson Reuters Life Sciences.
NuMedii’s Big Data technology uses machine learning, pattern matching, and network biology algorithms to find new indications for existing drugs.
Read the Full Story.